Possis RX Heart Catheter Approval, Anticipation Of AiMI Data Boost Stock
This article was originally published in The Gray Sheet
Executive Summary
Possis Medical's receipt of PMA supplement approval for coronary use of its AngioJet Rheolytic XMI-RX rapid exchange thrombectomy catheter helped propel the firm's stock ahead 12% in May to $28.49